Accuray Launches New CyberKnife® S7™ System

SUNNYVALE, Calif., June 17, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has launched the CyberKnife^® S7™ System, an innovative device combining speed, advanced precision, and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments — in as little as 15 minutes. The CyberKnife S7 System is the next-generation CyberKnife platform, a robotic, non-invasive radiation therapy device capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders. The new CyberKnife technology is the most recent illustration of Accuray innovation in radiation therapy that empowers healthcare providers through new capabilities to provide the best possible care to their patients.

Many changes can happen during treatment: the patient shifts position, breathes, or coughs, muscles tense and relax, fluids and gasses displace internal organs. This movement can impact the location of the tumor target when the radiation beam is delivered. The CyberKnife System's Synchrony^® motion synchronization technology uses AI to adapt radiation delivery in real-time to patient and/or tumor movement throughout the course of treatment. The system's robotic design facilitates the delivery of radiation from potentially thousands of unique angles, significantly expanding the possible positions from which radiation beams can be delivered. The more angles and points in space from which to approach the tumor, the better a physician will be able to maximize radiation dose delivered to the tumor and minimize dose to surrounding healthy tissues. The CyberKnife System is the only device capable of delivering sub-millimetric stereotactic treatments anywhere in the body with speed, efficiency and accuracy — all without the need for human intervention.

"Geisinger is dedicated to making exceptional cancer care available to residents of northeastern Pennsylvania, within their community," said chairman of radiation oncology at Geisinger Cancer Institute, Dr. Anand Mahadevan. "We are proud to be the first center in the world to treat patients with the CyberKnife S7 System, an advanced device that will expand the scope of tumors we can treat. Knowing that the system will automatically adapt treatment delivery for patient or tumor movement gives us the confidence to use SRS and SBRT for intra- and extra-cranial disease sites throughout the body, providing meaningful benefits to our patients during and after treatment."

Learn more about the CyberKnife S7 System here.

The CyberKnife S7 is built for the speed clinicians need for operational efficiency. Accurate, sub-millimetric, motion synchronized, (ultra) hypofractionated treatments can be delivered in as little as 15 minutes with Synchrony and the VOLO™ Optimizer, providing the patient throughput necessary to be successful in today's clinical environment. SRS and SBRT use advanced techniques to deliver precise, hypofractionated radiation therapy — which allows patients to be treated with very high doses of accurately targeted radiation administered in a few days versus conventional fractionation where treatments often require up to 35 visits. Patient benefits can include a shorter overall course of treatment and a significant reduction in the risk of side effects that can significantly impact patients' lives. 

Changes to the proposed Medicare & Medicaid Radiation Oncology – Alternative Payment Model favor the delivery of hypofractionated radiotherapy whenever clinically appropriate. Radiotherapy devices like the CyberKnife platform provide a resource for hospitals to achieve both their clinical efficacy and ROI goals.

"We are gratified to have achieved this important CyberKnife System milestone with the support from Dr. Mahadevan and his team. The CyberKnife system has continued to evolve since the first patient was treated more than 25 years ago and it remains the 'go to' device for clinicians who want to confidently deliver precise and accurate stereotactic treatments on a day-in, day-out basis," said Joshua H. Levine, president and CEO at Accuray. "With the introduction of the CyberKnife S7 System, Accuray is continuing its legacy of innovation. We believe this new system will make it easier for Geisinger clinicians to successfully deliver SRS and SBRT and achieve their patient-first treatment objectives, a priority for their team and ours."

About Accuray 
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor Statement 
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications and clinical results. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2020, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contacts 
Beth Kaplan  
Public Relations Director, Accuray 
+1 (408) 789-4426 
bkaplan@accuray.com 

Jayme Maniatis 
MSLGROUP 
+1 (781) 684-6610 
accuray@mslgroup.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-launches-new-cyberknife-s7-system-301078359.html

SOURCE Accuray Incorporated